Cargando…
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Measurable residual disease (MRD) evaluation may help to guide treatment duration in multiple myeloma (MM). Paradoxically, limited longitudinal data exist on MRD during maintenance. We investigated the prognostic value of MRD dynamics in 1280 transplant-eligible and -ineligible patients from the TOU...
Autores principales: | Paiva, Bruno, Manrique, Irene, Dimopoulos, Meletios A., Gay, Francesca, Min, Chang-Ki, Zweegman, Sonja, Špička, Ivan, Teipel, Raphael, Mateos, María-Victoria, Giuliani, Nicola, Cavo, Michele, Hopkins, Christine Rojas, Fu, Weijun, Suryanarayan, Kaveri, Vorog, Alexander, Li, Cong, Wang, Bingxia, Estevam, Jose, Labotka, Richard, Dash, Ajeeta B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651778/ https://www.ncbi.nlm.nih.gov/pubmed/36130300 http://dx.doi.org/10.1182/blood.2022016782 |
Ejemplares similares
-
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020) -
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
por: Kaiser, Martin, et al.
Publicado: (2020) -
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
por: Garderet, Laurent, et al.
Publicado: (2018) -
Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
por: Spencer, Andrew, et al.
Publicado: (2022) -
Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients
por: Srimani, Jaydeep K., et al.
Publicado: (2022)